News
CVRX
2.370
-0.84%
-0.020
Weekly Report: what happened at CVRX last week (0803-0807)?
Weekly Report · 1d ago
CVRx, Inc. (NASDAQ:CVRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Simply Wall St · 2d ago
CVRx (CVRX) Stock Reels From Guidance Cut And Cash Burn Fears
Simply Wall St · 3d ago
CVRx Price Target Cut to $3.50/Share From $14.00 by Lake Street
Dow Jones · 3d ago
CVRx Cut to Hold From Buy by Lake Street
Dow Jones · 3d ago
Lake Street Downgrades CVRx to Hold, Lowers Price Target to $3.5
Benzinga · 3d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 4d ago
CVRx downgraded to Hold from Buy at Lake Street
TipRanks · 4d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 4d ago
At a glance: stocks gapping down premarket
Seeking Alpha · 4d ago
CVRx downgraded to Hold from Buy at Craig-Hallum
TipRanks · 4d ago
CVRx price target lowered to $5 from $10 at Canaccord
TipRanks · 4d ago
CVRx Shares Slide on Sales View Cut
Dow Jones · 4d ago
CVRx downgraded to Neutral from Overweight at Piper Sandler
TipRanks · 4d ago
Why Atlassian Shares Are Trading Higher By More Than 30%; Here Are 20 Stocks Moving Premarket
Benzinga · 4d ago
CVRx Reports Q2 2026 Results, Shows Revenue Growth But Maintains Net Loss
NASDAQ · 4d ago
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Solid Biosciences (SLDB)
TipRanks · 4d ago
CVRx Stock Is Falling Overnight: Here's What's Driving the Move
Benzinga · 4d ago
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 4d ago
Compared to Estimates, CVRx (CVRX) Q2 Earnings: A Look at Key Metrics
NASDAQ · 4d ago
More
Webull provides a variety of real-time CVRX stock news. You can receive the latest news about Cvrx, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CVRX
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.